Clinical Trials · NCT05877547
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 381
- Start date
- Jun 2023
- Locations
- 175 sites, 26 countries
- Primary endpoint
- Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52